Vermillion Announces Issuance of Patent for Alzheimer's Disease Diagnosis

Bio-Medicine.Org

FREMONT, Calif., June 29 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Pink Sheets: VRML), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Biomarkers for Alzheimer's disease" to the Company. The patent claims are directed to biomarker combinations for the diagnosis and management of Alzheimer's disease and to the measurement of the biomarkers by a variety of methods, including mass spectrometry and immunoassay.

"The granting of our Alzheimer's disease biomarker patent is additional validation of our approach to intellectual property protection. We view the increasing breadth of our patent portfolio as a significant corporate asset," said Gail S. Page, CEO and Chairperson.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at www.vermillion.com [1].

About OVA1™

OVA1(TM) is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following crite
'/>"/>

SOURCE [2]

Source URL (retrieved on *09/02/2014 - 4:42pm*):
http://www.mdtmag.com/news/2010/06/vermillion-announces-issuance-patent-alzheimers-disease-diagnosis

Links:
[1] http://www.vermillion.com/
[2] http://www.bio-medicine.org/medicine-technology-1/Vermillion-Announces-Issuance-of-Patent-for-Alzheimers-Disease-Diagnosis-9499-1/